Alector Inc (ALEC)

$3.05 -0.09 (-2.87%)
Market Cap 311.73M
Revenue (ttm) 100.56M
Net Income (ttm) -119.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -118.39%
Debt to Equity Ratio 0.13
Volume 590,835
Avg Vol 1,398,484
Day's Range N/A - N/A
Shares Out 101.21M
Stochastic %K 62%
Beta 0.99
Analysts Sell
Price Target $3.83

Company Profile

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidat...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 231 5660
Address:
131 Oyster Point Boulevard, Suite 600, South San Francisco, United States
Doom_Gloom_AR
Doom_Gloom_AR Oct. 2 at 12:58 AM
$ALEC I'll buy this stock big and play the binary if someone can tell me why putting grn back into the brain will have any cognitive benefits in one year.
2 · Reply
John62
John62 Oct. 1 at 7:48 PM
$ALEC Started position here today 🤘
0 · Reply
jumanah1212
jumanah1212 Oct. 1 at 6:51 PM
$ALEC bullish 🚀🚀💸💵
0 · Reply
jumanah1212
jumanah1212 Sep. 24 at 4:50 PM
$ALEC Positive divergence which means BULLISH 💰🤑
0 · Reply
jumanah1212
jumanah1212 Sep. 24 at 1:34 PM
$ALEC
0 · Reply
revueltoL
revueltoL Sep. 23 at 1:58 AM
$ALEC beginning of a new chapter… go Alector!
0 · Reply
ParabolicHowl
ParabolicHowl Sep. 22 at 2:56 PM
Could everyone be moving to ticker ECDA now?! News released earlier - spiked to 6$ - looks like people are finding it again! ECDA has only 500k shares remaining to public, could be the next nano float squeezer! ECDA moves around on thin are - Don't miss ECDA! $MRM $PAPL $HTFL $ALEC mx
0 · Reply
jumanah1212
jumanah1212 Sep. 19 at 1:40 PM
$ALEC GAP should close soon🤑💰🚀
0 · Reply
Savatije
Savatije Sep. 19 at 5:20 AM
$ALEC money making machine
0 · Reply
Stekli27
Stekli27 Sep. 18 at 6:32 PM
$ALEC golden treasure? 😋
0 · Reply
Latest News on ALEC
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

Oct 10, 2025, 4:32 AM EDT - 10 hours ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX BDTX CHRS

Alector, Inc. - Special Call

Sep 22, 2025, 9:03 PM EDT - 17 days ago

Alector, Inc. - Special Call

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Sep 16, 2025, 8:00 AM EDT - 24 days ago

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 4:45 PM EDT - 4 weeks ago

Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alector to Participate in Upcoming Healthcare Conferences

Aug 28, 2025, 8:00 AM EDT - 6 weeks ago

Alector to Participate in Upcoming Healthcare Conferences

Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 2:35 AM EDT - 2 months ago

Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 4:05 PM EDT - 2 months ago

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

Jul 31, 2025, 4:05 PM EDT - 2 months ago

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

Alector Provides Executive Leadership Update

Jun 13, 2025, 4:05 PM EDT - 4 months ago

Alector Provides Executive Leadership Update

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 4 months ago

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 5 months ago

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

GSK

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 1:09 AM EST - 8 months ago

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:05 PM EST - 8 months ago

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Feb 19, 2025, 4:05 PM EST - 8 months ago

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Jan 13, 2025, 8:00 AM EST - 9 months ago

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Dec 4, 2024, 2:20 PM EST - 11 months ago

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Nov 26, 2024, 10:29 AM EST - 11 months ago

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Nov 25, 2024, 4:05 PM EST - 11 months ago

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Nov 14, 2024, 4:05 PM EST - 11 months ago

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:05 PM EST - 1 year ago

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 11:53 PM EDT - 1 year ago

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Alector to Host Mid-Year Earnings Conference Call

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Alector to Host Mid-Year Earnings Conference Call

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Jul 28, 2024, 8:05 AM EDT - 1 year ago

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 11:23 PM EST - 1 year ago

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 4:05 PM EST - 1 year ago

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Feb 20, 2024, 4:05 PM EST - 1 year ago

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

Feb 8, 2024, 7:00 AM EST - 1 year ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Feb 7, 2024, 7:00 AM EST - 1 year ago

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector Announces Closing of Public Offering

Jan 19, 2024, 9:20 AM EST - 1 year ago

Alector Announces Closing of Public Offering

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Jan 17, 2024, 5:32 PM EST - 1 year ago

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Alector Announces Pricing of Public Offering of Common Stock

Jan 17, 2024, 8:54 AM EST - 1 year ago

Alector Announces Pricing of Public Offering of Common Stock

Alector Announces Proposed Public Offering of Common Stock

Jan 16, 2024, 4:01 PM EST - 1 year ago

Alector Announces Proposed Public Offering of Common Stock

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16, 2024, 11:12 AM EST - 1 year ago

Alector: Good Data, Huge Cash, No Near Term Catalyst

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Nov 28, 2023, 7:00 AM EST - 2 years ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Alector to Participate in the Stifel Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 2 years ago

Alector to Participate in the Stifel Healthcare Conference

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 7, 2023, 4:05 PM EST - 2 years ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Oct 27, 2023, 7:00 AM EDT - 2 years ago

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript

Aug 4, 2023, 9:45 AM EDT - 2 years ago

Alector, Inc. (ALEC) Q2 2023 Earnings Call Transcript

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 2 years ago

Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

May 4, 2023, 4:05 PM EDT - 2 years ago

Alector Reports First Quarter 2023 Financial Results and Provides Business Update

Alector to Participate in the BofA Securities 2023 Healthcare Conference

May 2, 2023, 7:00 AM EDT - 2 years ago

Alector to Participate in the BofA Securities 2023 Healthcare Conference

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 28, 2023, 4:05 PM EST - 2 years ago

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Alector: Trading At Cash Despite Late Stage CNS Pipeline

Feb 3, 2023, 2:13 PM EST - 2 years ago

Alector: Trading At Cash Despite Late Stage CNS Pipeline

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 8, 2022, 4:30 PM EST - 3 years ago

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Nov 29, 2022, 11:05 AM EST - 3 years ago

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

Alector Announces Promotion of Clare Hunt to Chief People Officer

Oct 13, 2022, 8:00 AM EDT - 3 years ago

Alector Announces Promotion of Clare Hunt to Chief People Officer

Doom_Gloom_AR
Doom_Gloom_AR Oct. 2 at 12:58 AM
$ALEC I'll buy this stock big and play the binary if someone can tell me why putting grn back into the brain will have any cognitive benefits in one year.
2 · Reply
John62
John62 Oct. 1 at 7:48 PM
$ALEC Started position here today 🤘
0 · Reply
jumanah1212
jumanah1212 Oct. 1 at 6:51 PM
$ALEC bullish 🚀🚀💸💵
0 · Reply
jumanah1212
jumanah1212 Sep. 24 at 4:50 PM
$ALEC Positive divergence which means BULLISH 💰🤑
0 · Reply
jumanah1212
jumanah1212 Sep. 24 at 1:34 PM
$ALEC
0 · Reply
revueltoL
revueltoL Sep. 23 at 1:58 AM
$ALEC beginning of a new chapter… go Alector!
0 · Reply
ParabolicHowl
ParabolicHowl Sep. 22 at 2:56 PM
Could everyone be moving to ticker ECDA now?! News released earlier - spiked to 6$ - looks like people are finding it again! ECDA has only 500k shares remaining to public, could be the next nano float squeezer! ECDA moves around on thin are - Don't miss ECDA! $MRM $PAPL $HTFL $ALEC mx
0 · Reply
jumanah1212
jumanah1212 Sep. 19 at 1:40 PM
$ALEC GAP should close soon🤑💰🚀
0 · Reply
Savatije
Savatije Sep. 19 at 5:20 AM
$ALEC money making machine
0 · Reply
Stekli27
Stekli27 Sep. 18 at 6:32 PM
$ALEC golden treasure? 😋
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 9:30 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $LHAI $TGE $STEM $ONCY $ALEC
0 · Reply
CrispDry
CrispDry Sep. 17 at 9:25 PM
$ALEC anyone have a TAM for this one?
1 · Reply
Woodmont
Woodmont Sep. 12 at 3:18 PM
$ALEC Someone knows something look at today’s volume
0 · Reply
manymore
manymore Sep. 6 at 12:43 AM
$ALEC $LXRX well that's another 50% on top of the 47% all in 1 month - ramping up from $0.87 in April and in anticipation of phase 3 results mid Q4 ... $6-$12 if results are great Elevators down if not Waiting for LXRX to take off!!
1 · Reply
revueltoL
revueltoL Sep. 4 at 5:53 PM
$ALEC slow and steady wins the race 🤣
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 6:30 AM
$ALEC Really good write-up that perfectly summarizes ALEC's present situation. So if you want to bring your ALEC knowledge up to date or just discover ALEC, this is required reading. https://beyondspx.com/quote/ALEC/alector-s-pivotal-moment-unlocking-neurodegeneration-s-future-with-latozinemab-and-brain-carrier-innovation-nasdaq-alec#analysis
0 · Reply
MidasTouchTraders
MidasTouchTraders Sep. 2 at 11:22 PM
$TERN $ALEC $ULCC Lets get these going! #HAPPYTRADING
0 · Reply
Slitherin
Slitherin Sep. 2 at 7:47 PM
Ticker CARV has a tiny 3M float and $700M in assets with around $50M cash compared to a $10M Market cap. This could easily 2-3X. Rate cuts will boost banking stocks in September. $MATH $ALEC $STRO $AXTI $JFB on watch for AH
0 · Reply
revueltoL
revueltoL Sep. 2 at 6:19 PM
$ALEC undervalued is an understatement 🤣
0 · Reply
cloudforever
cloudforever Sep. 2 at 4:12 PM
$ALEC undervalued
0 · Reply
revueltoL
revueltoL Aug. 29 at 7:33 PM
$ALEC i’m ahead of the game… an onslaught of bullish meme fest will hit here… in time.
0 · Reply
BocaDon
BocaDon Aug. 25 at 3:44 PM
$DKI thank you, now $RR and $ALEC pay me..
1 · Reply